

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

31

Application Number

10/667,187

Filing Date

September 17, 2003

First Named Inventor

Michael J. Munchhof

Art Unit

1625

Examiner Name

Owens, Amelia A

Attorney Docket Number

PC25292A

RECEIVED
CENTRAL FAX CENTER
AUG 10 2006**ENCLOSURES (Check all that apply)**

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/
Incomplete ApplicationReply to Missing Parts
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a
Provisional Application

Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____



Landscape Table on CD



After Allowance Communication to TC

Appeal Communication to Board
of Appeals and InterferencesAppeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

Proprietary Information




Status Letter

Other Enclosure(s) (please identify
below):**Remarks**Authorization to charge the fee and any additional fees as necessary or credit any
overpayment to deposit account 23-0455 is hereby given.**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

Pfizer Inc.

Signature



Printed name

Rosanne Goodman

Date

August 10, 2006

Reg. No.

32,534

CERTIFICATE OF TRANSMISSION/MAILINGI hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with
sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
the date shown below:

Signature



Typed or printed name

Cindy Malocha

Date

August 10, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTO Fax No. 571-273-8300

Appl. No. : 10/667,187 Confirmation No.: 9326
Applicant : Michael J. Munchhof
Filed : September 17, 2003
Title : NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS
TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS
TC/A.U. : 1625
Examiner : OWENS, AMELIA A.
Docket No. : PC25292A
Customer No. : 28880

RECEIVED
CENTRAL FAX CENTER
AUG 10 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Dear Sir:

This paper is responsive to the Office Action mailed on May 10, 2006, with respect to the above-identified application and is being timely filed within three months of the date of the Office Action. Please consider the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begin on page 2 of this paper.

Remarks/Arguments begin on page 28 of this paper.